Cytokinetics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Cytokinetics and other ETFs, options, and stocks.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

423

Employees423

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

423

Employees423

CYTK Key Statistics

Market cap

5.73B

Market cap5.73B

Price-Earnings ratio

-9.01

Price-Earnings ratio-9.01

Dividend yield

—

Dividend yield—

Average volume

1.39M

Average volume1.39M

High today

$48.95

High today$48.95

Low today

$47.99

Low today$47.99

Open price

$48.14

Open price$48.14

Volume

637.14K

Volume637.14K

52 Week high

$110.25

52 Week high$110.25

52 Week low

$45.66

52 Week low$45.66

CYTK News

Seeking Alpha 3d

Cytokinetics' aficamten application validated by EU regulators

Cytokinetics (NASDAQ:CYTK) said EU regulators have validated the market application for its drug aficamten for the treatment of obstructive hypertrophic cardiom...

TipRanks 7d

Sanofi to acquire rights to develop, commercialize aficamten from Corxel

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatme...

Analyst ratings

78%

of 18 ratings

Buy

77.8%

Hold

22.2%

Sell